0001232524-21-000061 | 10-Q | XBRL Viewer

Certain Balance Sheet Items - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$ 207,793	$ 127,534
Accrued interest	35,102	5,722
Clinical trial accruals	24,731	9,108
Current portion of lease liabilities	17,045	14,457
Sales return reserve	11,768	18,368
Inventory-related accruals	8,553	9,809
Accrued construction-in-progress	$ 5,031	$ 1,119

Label	Element	Value
Contract With Customer, Liability, Increase (Decrease) For Governmental Grant	jazz_ContractWithCustomerLiabilityIncreaseDecreaseForGovernmentalGrant	$ 484,000
Provision For Losses On Accounts Receivable And Inventory	jazz_ProvisionForLossesOnAccountsReceivableAndInventory	13,444,000
Provision For Losses On Accounts Receivable And Inventory	jazz_ProvisionForLossesOnAccountsReceivableAndInventory	9,148,000
Business Acquisition, Transactions Costs Incurred During Period	jazz_BusinessAcquisitionTransactionsCostsIncurredDuringPeriod	1,400,000
Business Acquisition, Transactions Costs Incurred During Period	jazz_BusinessAcquisitionTransactionsCostsIncurredDuringPeriod	85,400,000
Income Tax Examination, Penalties And Interest Paid	jazz_IncomeTaxExaminationPenaltiesAndInterestPaid	19,700,000
Nonvoting Euro Deferred Shares	jazz_NonvotingEuroDeferredShares	55,000
Nonvoting Euro Deferred Shares	jazz_NonvotingEuroDeferredShares	55,000
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets (Liabilities)	jazz_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilities	35,194,000
Long-Term Debt, Maturity, After Year Four	jazz_LongTermDebtMaturityAfterYearFour	5,942,958,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	145,224,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	42,095,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	304,607,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	98,760,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	(6,400,000)
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	80,100,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	74,100,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	222,200,000
Debt Covenant, Outstanding Amount Threshold	jazz_DebtCovenantOutstandingAmountThreshold	50,000,000
Capital Redemption Reserve	jazz_CapitalRedemptionReserve	472,000
Capital Redemption Reserve	jazz_CapitalRedemptionReserve	472,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedDuringPeriod	25,800,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedDuringPeriod	373,500,000
Increase (Decrease) In Operating Lease Liabilities, Noncurrent	jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	(13,423,000)
Increase (Decrease) In Operating Lease Liabilities, Noncurrent	jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	(9,884,000)
Payment To Acquire Assets, Net Of Cash Acquired	jazz_PaymentToAcquireAssetsNetOfCashAcquired	6,234,792,000
Payment To Acquire Assets, Net Of Cash Acquired	jazz_PaymentToAcquireAssetsNetOfCashAcquired	0
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(12,069,000)
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(12,069,000)
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(444,000)
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(444,000)
U.K. Finance Act, Change In Tax Rate, Deferred Tax Liability, Income Tax Expense (Benefit)	jazz_UKFinanceActChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit	250,600,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs Not Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostsNotExpensedDuringPeriod	30,500,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs Not Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostsNotExpensedDuringPeriod	330,400,000
Inventory, Step-Up Value	jazz_InventoryStepUpValue	884,000,000
Increase (Decrease) In Operating Lease Assets	jazz_IncreaseDecreaseInOperatingLeaseAssets	(12,054,000)
Increase (Decrease) In Operating Lease Assets	jazz_IncreaseDecreaseInOperatingLeaseAssets	(9,730,000)
De-recognition Of Operating Lease Asset On Lease Assignment	jazz_DeRecognitionOfOperatingLeaseAssetOnLeaseAssignment	56,968,000
De-recognition Of Operating Lease Asset On Lease Assignment	jazz_DeRecognitionOfOperatingLeaseAssetOnLeaseAssignment	0
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities	jazz_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities	$ 131,971,000
Revenue, Performance Obligation, Payment Terms	jazz_RevenuePerformanceObligationPaymentTerms	30 days
Revenue, Performance Obligation, Payment Terms	jazz_RevenuePerformanceObligationPaymentTerms	45 days
Payments to Acquire In Process Research and Development Other Than Through Business Combination	jazz_PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	$ 0
Payments to Acquire In Process Research and Development Other Than Through Business Combination	jazz_PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	215,250,000
Noncash Interest Expense	jazz_NoncashInterestExpense	66,055,000
Noncash Interest Expense	jazz_NoncashInterestExpense	45,702,000
De-recognition Of Operating Lease Liability On Lease Assignment	jazz_DeRecognitionOfOperatingLeaseLiabilityOnLeaseAssignment	68,064,000
De-recognition Of Operating Lease Liability On Lease Assignment	jazz_DeRecognitionOfOperatingLeaseLiabilityOnLeaseAssignment	0
Lessee, Operating Lease, Liability, To Be Paid, After Year Four	jazz_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	47,278,000
Finance Lease, Liability, To Be Paid, After Year Four	jazz_FinanceLeaseLiabilityToBePaidAfterYearFour	6,967,000
Finite-Lived Intangible Asset, Expected Amortization, After Year Four	jazz_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	$ 4,471,903,000
Licensing Agreement, Number Of Agreements	jazz_LicensingAgreementNumberOfAgreements	2
Infringed Patents Suit, Number Of Patents	jazz_InfringedPatentsSuitNumberOfPatents	5
Infringed Patents Suit, Number Of Patents	jazz_InfringedPatentsSuitNumberOfPatents	10
Operating And Finance Lease, Liability	jazz_OperatingAndFinanceLeaseLiability	$ 112,764,000
Operating And Finance Lease, Liability	jazz_OperatingAndFinanceLeaseLiability	154,492,000
Proceeds From Issuance Of Term Loan	jazz_ProceedsFromIssuanceOfTermLoan	3,719,930,000
Proceeds From Issuance Of Term Loan	jazz_ProceedsFromIssuanceOfTermLoan	$ 0
FDA Stay Of Approval Period	jazz_FDAStayOfApprovalPeriod	30 months
Operating Lease And Finance Lease Right-Of Use Asset	jazz_OperatingLeaseAndFinanceLeaseRightOfUseAsset	$ 95,481,000
Operating Lease And Finance Lease Right-Of Use Asset	jazz_OperatingLeaseAndFinanceLeaseRightOfUseAsset	$ 129,169,000
Business Combination, Number Of American Depository Shares Acquired	jazz_BusinessCombinationNumberOfAmericanDepositorySharesAcquired	31,556,200
Inventory Step-Up Value Adjustment	jazz_InventoryStepUpValueAdjustment	$ 148,637,000
Inventory Step-Up Value Adjustment	jazz_InventoryStepUpValueAdjustment	$ 0
FDA Recognition Of Orphan Drug Exclusivity, Period	jazz_FDARecognitionOfOrphanDrugExclusivityPeriod	7 years
Finite-Lived Intangible Asset, Measurement Input	jazz_FiniteLivedIntangibleAssetMeasurementInput	0.094

Certain Balance Sheet Items - Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Certain Balance Sheet Items [Abstract]
Deferred charge for taxes on intercompany profit	$ 183,833	$ 114,234

Print Document View Excel Document
Notes Details Certain Balance Sheet Items - Other Current Assets (Details) Certain Balance Sheet Items - Accrued Liabilities (Details) Uncategorized Uncategorized Items - jazz-20210930_htm.xml All Reports